THURSDAY, SEPTEMBER 29, 2016

ACIP updates pneumococcal conjugate vaccine recommendations

The Advisory Committee on Immunization Practices recently updated its recommendations on using 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine with immunocompromised children, the Centers for Disease Control and Prevention said on Friday.

The ACIP recommended that children between the ages of six and 18 years who have yet to receive PCV13 and are at increased risk for invasive pneumococcal disease should receive a single dose of PCV13 first, followed eight or more weeks later by a dose of PPSV23. Immunocompromised children include those with increased IPD risk from anatomical or functional asplenia, cochlear implant, HIV infection, cerebrospinal fluid leak or other immunocompromising conditions.

The committee recommended that the group receive a second PPSV23 dose five years after receiving the first PPSV23 dose.

The ACIP also made recommendations for children with immunocompromising conditions who previously received one or more doses of PPSV23. This group of children should receive a single PCV13 dose, eight or more weeks after the last PPSV23, even if they previously received 7-valent pneumococcal conjugate vaccine. If a second PPSV23 dose is indicated in an immunocompromised child, the dose should be given five or more years following the first PPSV23 dose. The children should not receive more than two doses of PPSV23 prior to the age of 65.

The committee made its recommendations because of the high burden of IPD caused by serotypes of PPSV23 that aren't included in PCV13. The ACIP found broader protection could be provided through using both PCV13 and PPSV23.

According to the CDC, Streptococcus pneumoniae is a leading cause of serious infections, including meningitis and sepsis. The bacterium accounts for significant mortality and morbidity in the U.S.